200 related articles for article (PubMed ID: 35286522)
1. Differences in somatic TP53 mutation type in breast tumors by race and receptor status.
Pollock NC; Ramroop JR; Hampel H; Troester MA; Conway K; Hu JJ; Freudenheim JL; Olopade OI; Huo D; Ziv E; Neuhausen SL; Stevens P; McElroy JP; Toland AE
Breast Cancer Res Treat; 2022 Apr; 192(3):639-648. PubMed ID: 35286522
[TBL] [Abstract][Full Text] [Related]
2. Association of
Tjader NP; Beer AJ; Ramroop J; Tai MC; Ping J; Gandhi T; Dauch C; Neuhausen SL; Ziv E; Sotelo N; Ghanekar S; Meadows O; Paredes M; Gillespie J; Aeilts A; Hampel H; Zheng W; Jia G; Hu Q; Wei L; Liu S; Ambrosone CB; Palmer JR; Carpten JD; Yao S; Stevens P; Ho WK; Pan JW; Fadda P; Huo D; Teo SH; McElroy JP; Toland AE
medRxiv; 2023 Dec; ():. PubMed ID: 38106140
[TBL] [Abstract][Full Text] [Related]
3. Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.
Guerini-Rocco E; Piscuoglio S; Ng CK; Geyer FC; De Filippo MR; Eberle CA; Akram M; Fusco N; Ichihara S; Sakr RA; Yatabe Y; Vincent-Salomon A; Rakha EA; Ellis IO; Wen YH; Weigelt B; Schnitt SJ; Reis-Filho JS
J Pathol; 2016 Apr; 238(5):677-88. PubMed ID: 26806567
[TBL] [Abstract][Full Text] [Related]
4. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
5. Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
Lee S; Kim HY; Jung YJ; Jung CS; Im D; Kim JY; Lee SM; Oh SH
Curr Probl Cancer; 2022 Apr; 46(2):100843. PubMed ID: 35180531
[TBL] [Abstract][Full Text] [Related]
6. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
7. Association between Mutation and Expression of
Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
[TBL] [Abstract][Full Text] [Related]
8. Germline TP53 and MSH6 mutations implicated in sporadic triple-negative breast cancer (TNBC): a preliminary study.
Yi D; Xu L; Luo J; You X; Huang T; Zi Y; Li X; Wang R; Zhong Z; Tang X; Li A; Shi Y; Rao J; Zhang Y; Sang J
Hum Genomics; 2019 Jan; 13(1):4. PubMed ID: 30630526
[TBL] [Abstract][Full Text] [Related]
9. Somatic mutations of triple-negative breast cancer: a comparison between Black and White women.
Omilian AR; Wei L; Hong CC; Bandera EV; Liu S; Khoury T; Ambrosone CB; Yao S
Breast Cancer Res Treat; 2020 Jul; 182(2):503-509. PubMed ID: 32441016
[TBL] [Abstract][Full Text] [Related]
10. Ultrasonic Features and Molecular Subtype Predict Somatic Mutations in TP53 and PIK3CA Genes in Breast Cancer.
Huang Y; Qiang Y; Jian L; Jin Z; Lang Q; Sheng C; Shichong Z; Cai C
Acad Radiol; 2022 Dec; 29(12):e261-e270. PubMed ID: 35450798
[TBL] [Abstract][Full Text] [Related]
11. Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient.
Shtraizent N; Matsui H; Polotskaia A; Bargonetti J
Int J Environ Res Public Health; 2015 Dec; 13(1):ijerph13010022. PubMed ID: 26703669
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence.
Keenan T; Moy B; Mroz EA; Ross K; Niemierko A; Rocco JW; Isakoff S; Ellisen LW; Bardia A
J Clin Oncol; 2015 Nov; 33(31):3621-7. PubMed ID: 26371147
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
[TBL] [Abstract][Full Text] [Related]
14. Translational Epidemiology: An Integrative Approach to Determine the Interplay Between Genetic Ancestry and Neighborhood Socioeconomic Status on Triple Negative Breast Cancer.
Goel N; Yadegarynia S; Kwon D; Kesmodel SB; Harbour JW; Kobetz E; Merchant N; Rodriguez DA
Ann Surg; 2022 Sep; 276(3):430-440. PubMed ID: 35758508
[TBL] [Abstract][Full Text] [Related]
15. Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.
Kim J; Jeong K; Jun H; Kim K; Bae JM; Song MG; Yi H; Park S; Woo GU; Lee DW; Kim TY; Lee KH; Im SA
Hum Genomics; 2023 Jan; 17(1):2. PubMed ID: 36604691
[TBL] [Abstract][Full Text] [Related]
16. Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women.
O'Meara T; Safonov A; Casadevall D; Qing T; Silber A; Killelea B; Hatzis C; Pusztai L
Breast Cancer Res Treat; 2019 May; 175(1):247-259. PubMed ID: 30725384
[TBL] [Abstract][Full Text] [Related]
17. The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.
Guerini-Rocco E; Hodi Z; Piscuoglio S; Ng CK; Rakha EA; Schultheis AM; Marchiò C; da Cruz Paula A; De Filippo MR; Martelotto LG; De Mattos-Arruda L; Edelweiss M; Jungbluth AA; Fusco N; Norton L; Weigelt B; Ellis IO; Reis-Filho JS
J Pathol; 2015 Oct; 237(2):166-78. PubMed ID: 26011570
[TBL] [Abstract][Full Text] [Related]
18. Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians.
Ademuyiwa FO; Tao Y; Luo J; Weilbaecher K; Ma CX
Breast Cancer Res Treat; 2017 Feb; 161(3):491-499. PubMed ID: 27915434
[TBL] [Abstract][Full Text] [Related]
19. Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data.
Schinkel JK; Zahm SH; Jatoi I; McGlynn KA; Gallagher C; Schairer C; Shriver CD; Zhu K
Cancer Causes Control; 2014 Aug; 25(8):959-68. PubMed ID: 24839049
[TBL] [Abstract][Full Text] [Related]
20. TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer.
Mukhopadhyay UK; Oturkar CC; Adams C; Wickramasekera N; Bansal S; Medisetty R; Miller A; Swetzig WM; Silwal-Pandit L; Børresen-Dale AL; Creighton CJ; Park JH; Konduri SD; Mukhopadhyay A; Caradori A; Omilian A; Bshara W; Kaipparettu BA; Das GM
J Natl Cancer Inst; 2019 Nov; 111(11):1202-1215. PubMed ID: 30990221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
